A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update.

ABSTRACT:

Purpose

We evaluated the effectiveness of additional risk minimisation measures (aRMMs; i.e., educational materials) distributed to prescribers to ensure that only individuals with evidence of prior dengue infection (PDI, i.e., dengue seropositive) would be vaccinated with the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®).

Methods

A survey was conducted in 2020 among 300 CYD-TDV prescribers in Brazil and Thailand to ascertain three success criteria: prescribers' awareness of the materials (receiving and reading them); knowledge of the key messages; and whether their self-reported behaviour regarding practice-related scenarios was aligned with the updated guidance.

Results

The aRMMs were not generally effective as <80% of prescribers in both countries met two of the

SUBMITTER: Almas MF 

PROVIDER: S-EPMC9325459 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature